According to new data released on Tuesday, a booster dose of Johnson & Johnson’s vaccine given two months after the one-shot vaccination provides 94 percent protection against moderate-to-severe COVID-19 symptoms.
The booster shot, according to J&J, provides 100 percent protection against severe or critical symptoms, citing three tests of the vaccine. According to the company, a six-month booster dose after the initial shot provides even more excellent protection. The findings corroborate data from Moderna and Pfizer-BioNTech vaccination research, per USA Today.
Pfizer’s COVID-19 Vaccine’s Efficacy
The one-dose J&J vaccination was found to be 66% protective against moderate-to-severe illness globally and 72% protective in the United States. Furthermore, according to Johnson & Johnson’s chief scientific officer, Dr. Paul Stoffels, it’s critical to vaccinate the global population with a single-shot COVID-19 vaccine that’s easy to use, distribute, and administer while also providing strong and long-lasting protection. Thus, A booster dose improves COVID-19 protection even more and is projected to increase the length of protection considerably,
Because the J&J vaccine was approved roughly two months later than the Moderna and Pfizer/BioNTech vaccines, its data has been delayed. Johnson & Johnson has stated that it will submit all of this information to the FDA to consider adding a booster dose and possibly authorizing a two-dose regimen.
Pfizer’s COVID-19 Vaccine: Safe for Children?
The Janssen vaccine is developed using a different technique than the vaccines produced by Moderna and Pfizer. They carry messenger RNA, also known as mRNA, to the body encased in lipids. The J&J vaccine is manufactured with adenovirus, a common cold virus modified to enter cells but then ceases. This is how genetic instructions are delivered. Hence, the findings follow Pfizer-announcement BioNTech’s that their vaccinations are safe and effective for children aged 5 to 11 at one-third the dose used in adolescents and adults.
According to Dr. Dan Barouch, head of Beth Israel Deaconess’ Center for Virology and Vaccine Research, the J&J vaccine may look less successful in nations other than the United States since it was tested in numerous countries at a time when variations that can circumvent vaccine protection were circulating – CNN. The Beta or B.1.351 form, for example, includes so-called escape mutations that allow it to evade the immune system’s detection. It was widely distributed in South Africa, but Delta has outcompeted it in the United States, despite the fact that Delta does not appear to be immune-protected.